Dynavax Technologies  (NASDAQ:DVAX) shares inched up today following the release of the company's Q3 results. For the quarter, revenues came in at $2.93 million, up modestly from the $2.87 million in the same period the previous year. The firm managed to narrow its loss during the period, posting a $15.7 million ($0.09 per diluted share) shortfall against Q3 2012's loss of $17.8 million ($0.10).

Last month, the company concurrently floated common and preferred stock issues. The estimated gross proceeds from both were pegged at $132 million. At the end of its Q3, Dynavax's cash, cash equivalents, and marketable securities stood at $76.5 million.

In trading today, the company's stock crept upwards by 0.5%, or $0.01, to $1.12.